- Citations, last 5 years
- 45
- Works, last 5 years
- 10
- h-index
- 17
- Scientists listed
- 1
- Grants since 2016
- 14
Grants received
2025–2026 · research · R21
Novel medical countermeasure to mitigate potentially lethal acute radiation syndrome
Alexander B Sigalov · SignaBlok (United States) · funded by National Institutes of Health
2025–2026 · research · R43
TREM-1 therapy for the treatment of empyema
Alexander B Sigalov · SignaBlok (United States) · funded by National Institutes of Health
2023–2024 · research · R44
First-in-class TREM-1 inhibitors for neovascular retinal diseases
Alexander B Sigalov · SignaBlok (United States) · funded by National Institutes of Health
2023–2024 · research · R43
New mechanism-based TREM-1 therapy for acute respiratory distress syndrome
Alexander B Sigalov · SignaBlok (United States) · funded by National Institutes of Health
2023–2027 · research · R44
First-in-class TREM-1 inhibitors for neovascular retinal diseases
Alexander B Sigalov · SignaBlok (United States) · funded by National Institutes of Health
2020–2022 · research · R44
TREM-1 therapy for rheumatoid arthritis
Alexander B Sigalov · SignaBlok (United States) · funded by National Institutes of Health
2020–2022 · research · R43
TREM-1 inhibitor for the treatment of scleroderma
Alexander B Sigalov · SignaBlok (United States) · funded by National Institutes of Health
2018–2021 · research · R43
Novel TREM-1 targeting therapies for sepsis
Alexander B Sigalov · SignaBlok (United States) · funded by National Institutes of Health
2018–2021 · research · R43
Development of first-in-class TREM-1 inhibitors for neovascular retinal diseases
Alexander B Sigalov · SignaBlok (United States) · funded by National Institutes of Health
2017–2021 · research · R44
First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer
Alexander B Sigalov · SignaBlok (United States) · funded by National Institutes of Health
2017–2023 · research · R44
First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer
Alexander B Sigalov · SignaBlok (United States) · funded by National Institutes of Health
2017–2019 · research · R43
First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer
Alexander B Sigalov · SignaBlok (United States) · funded by National Institutes of Health
2017–2019 · research · R43
First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer
Alexander B Sigalov · SignaBlok (United States) · funded by National Institutes of Health
2016–2018 · research · R43
Treatment of alcoholic liver disease with novel targeted inhibitors
Alexander B Sigalov · SignaBlok (United States) · funded by National Institutes of Health
